Chemotherapy

Model Suggests Surgery Should Come Before Chemotherapy for Select Patients with Aggressive Ovarian Cancer

Retrieved on: 
Monday, June 14, 2021
Medicine, Clinical medicine, Cancer, Oncology, Gynaecology, Cancer treatments, Gynaecological cancer, Ovarian cancer, Chemotherapy, Debulking, Malignancy, Hyperthermic intraperitoneal chemotherapy

Ovarian cancer is the 8th most common cancer and cancer death in women worldwide, and HGSC constitutes roughly 70 percent of ovarian malignancies and has the worst prognosis.

Key Points: 
  • Ovarian cancer is the 8th most common cancer and cancer death in women worldwide, and HGSC constitutes roughly 70 percent of ovarian malignancies and has the worst prognosis.
  • Patients with the condition typically undergo surgery and chemotherapy, but there has been long-standing controversy over the best order of treatment.
  • The researchers found that in patients who are well enough for surgery, debulking provides better results because it has the best chance of removing cancer cells resistant to chemotherapy.
  • For patients who are too ill for debulking surgery, the study suggests that a shorter period of initial chemotherapy, rather than the currently recommended interval, might provide a greater benefit.

G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer

Retrieved on: 
Monday, June 14, 2021
Cancer, Clinical medicine, Chemical compounds, Breakthrough therapy, G1 Therapeutics, Infectious causes of cancer, Orphan drugs, Trilaciclib, Bladder cancer, Avelumab, Chemotherapy, Gemcitabine

Arm B will receive COSELA prior to gemcitabine/platinum chemotherapy followed by COSELA plus avelumab maintenance therapy.

Key Points: 
  • Arm B will receive COSELA prior to gemcitabine/platinum chemotherapy followed by COSELA plus avelumab maintenance therapy.
  • Bladder cancer is the most common malignancy involving the urinary system and is the sixth most common cancer in the United States.
  • The American Cancer Society estimates that approximately 84,000 new cases of bladder cancer will be diagnosed in the U.S. in 2021.
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.

Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual Meeting

Retrieved on: 
Monday, June 7, 2021
Cancer, Clinical medicine, Medicine, Histopathology, Prostate cancer, Chemotherapy, Prostvac, Pelareorep

The Phase 1b/2 clinical study was designed as a dynamic study with an initial 3+3 standard safety study component followed by an expanded study with increases in dose and schedule.

Key Points: 
  • The Phase 1b/2 clinical study was designed as a dynamic study with an initial 3+3 standard safety study component followed by an expanded study with increases in dose and schedule.
  • The Phase 1b/2 clinical trial enrolled 80 men and is ongoing with patients in both the Phase 1b and 2 components still on study.
  • Two of these patients on continuous daily dosing of sabizabulin have now reached 27 months and 23 months of treatment without prostate cancer progression.
  • (2) Phase 2 clinical study for the treatment of women with metastatic triple negative breast cancer who have become resistant to at least two systemic chemotherapies.

POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC

Retrieved on: 
Friday, June 4, 2021
Oncology, Health, Clinical trials, Radiology, Pharmaceutical, Biotechnology, Organic compounds, Chemical compounds, Hormones, Prostate cancer, Enzalutamide, Abiraterone acetate, Chemotherapy, CBR96-doxorubicin immunoconjugate, POINT Biopharma, Therapeutics Acquisition Corp, d/b/a Research Alliance Corp. I, RA Capital Management, POINT BIOPHARMA, THERAPEUTICS ACQUISITION CORP, D/B/A RESEARCH ALLIANCE CORP. I, RA CAPITAL MANAGEMENT

The Phase 3 SPLASH study is a multi-center, randomized, open label assessment of PNT2002 in patients with mCRPC who have progressed on ARAT therapy and refuse or not eligible for chemotherapy.

Key Points: 
  • The Phase 3 SPLASH study is a multi-center, randomized, open label assessment of PNT2002 in patients with mCRPC who have progressed on ARAT therapy and refuse or not eligible for chemotherapy.
  • Patients will be randomized 2:1 with patients in arm A receiving PNT2002 and patients in arm B receiving either Abiraterone or Enzalutamide.
  • We are pleased to announce dosing of patients in our Phase 3 SPLASH study, which represents a significant milestone for POINT.
  • The current standard of care is not sufficient for patients with this aggressive form of cancer, said Dr. Nordquist.

Biosight Presents Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) in an Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Clinical medicine, Medicine, Cancer, Cancer treatments, Chemotherapy, Occupational safety and health, Oncology, Cytarabine, 7+3, Dose

Due to its unique pharmacokinetics and metabolism, aspacytarabine enables high-dose therapy with lower systemic exposure to free cytarabine and relative sparing of normal tissues.

Key Points: 
  • Due to its unique pharmacokinetics and metabolism, aspacytarabine enables high-dose therapy with lower systemic exposure to free cytarabine and relative sparing of normal tissues.
  • For more information regarding the Phase 2b clinical study of BST-236, please visit www.clinicaltrials.gov .
  • Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders.
  • Biosights lead product, aspacytarabine (BST-236), is an innovative proprietary anti-metabolite which addresses unmet medical needs by enabling high-dose chemotherapy with reduced systemic toxicity.

POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC

Retrieved on: 
Friday, June 4, 2021
Organic compounds, Chemical compounds, Hormones, Prostate cancer, Enzalutamide, Abiraterone acetate, Chemotherapy

The Phase 3 SPLASH study is a multi-center, randomized, open label assessment of PNT2002 in patients with mCRPC who have progressed on ARAT therapy and refuse or not eligible for chemotherapy.

Key Points: 
  • The Phase 3 SPLASH study is a multi-center, randomized, open label assessment of PNT2002 in patients with mCRPC who have progressed on ARAT therapy and refuse or not eligible for chemotherapy.
  • Patients will be randomized 2:1 with patients in arm A receiving PNT2002 and patients in arm B receiving either Abiraterone or Enzalutamide.
  • We are pleased to announce dosing of patients in our Phase 3 SPLASH study, which represents a significant milestone for POINT.
  • POINT Biopharma is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer.

Delcath Systems to Present at LD Micro Virtual Investor Conference on June 10, 2021, at 2:30pm ET

Retrieved on: 
Thursday, June 3, 2021
Medicine, Clinical medicine, Medical specialties, Oncology, Cancer, Hepatology, Delcath Systems, Chemotherapy, Interventional oncology, Liver cancer, Selective internal radiation therapy

For more information on the LD Micro Invitational XI, or to register for the event, please visit https://ldmicrojune2021.mysequire.com .

Key Points: 
  • For more information on the LD Micro Invitational XI, or to register for the event, please visit https://ldmicrojune2021.mysequire.com .
  • Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
  • Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
  • HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.

Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021

Retrieved on: 
Wednesday, June 2, 2021
Clinical medicine, Chemical compounds, Medicine, Antineoplastic drugs, Orphan drugs, Pyrazines, Selinexor, Teratogens, Triazoles, Multiple myeloma, Dexamethasone, Chemotherapy

Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.

Key Points: 
  • Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.
  • SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.
  • A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.
  • Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study.

Toxoplasmosis Treatment Drugs Market Report - Global Size, Share, Outlook, and Opportunity Analysis, 2016-2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 27, 2021
General Health, Pharmaceutical, Health, Clinical medicine, Medicine, Conoidasida, Health, Biology of bipolar disorder, Biology of obsessive–compulsive disorder, Toxoplasmosis, Zoonoses, Toxoplasma gondii, Chemotherapy

The "Toxoplasmosis Treatment Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Toxoplasmosis Treatment Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Rising number of chemotherapy procedures can lead to increase in the number of toxoplasmosis infection thereby assisting the market growth.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
    The global toxoplasmosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
    Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global toxoplasmosis treatment drugs market.
  • Global Toxoplasmosis Treatment Drugs Market, By Indication:
    Global Toxoplasmosis Treatment Drugs Market, By Route of Administration:
    Global Toxoplasmosis Treatment Drugs Market, By Drug Class:

Delcath Systems to Present at Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021
Medicine, Clinical medicine, Medical specialties, Cancer, Oncology, Hepatology, Delcath Systems, Interventional oncology, Liver cancer, Chemotherapy, Liver

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at:

Key Points: 
  • NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at:
    Jefferies Virtual Healthcare Conference on June 3, 2021 at 4:00 PM (ET)
    For more information or to schedule a one-on-one meeting with management, please contact your conference representative or [email protected].
  • Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
  • Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
  • HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.